Following recent publications and anticipating the readout from its NILE study next year, the company plans to make the case that its liquid biopsy approach performs as well as tissue tests.

Relying on artificial intelligence, the company has crafted a software tool to assist pathologists in diagnosing cancers and delivering clinical reports.

The new services geared toward wellness testing enable patients to order test kits without visiting their doctor.

The team said it will partner with startup Early Diagnostics to commercialize the assay, which integrates DNA methylation analysis and computational technology.

The agreement amends and restates an existing loan and security agreement between NanoString and SVB to increase the size of the revolving loan facility to $20 million.